For the quarter ending 2026-03-31, ONCO had -$1,504,582 decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Change in fair value of warrant liabilities | - | - | -1,934,000 | - |
| Change in fair value of series d warrant liability | - | 10,377,638 | - | - |
| Change in fair value of series d derivative liability | - | 3,593,333 | 216,000 | - |
| Loss on impairment of entadfi | - | 0 | 0 | 0 |
| Change in fair value of subscription agreement liability | - | 0 | 0 | 3,127,962 |
| Loss on impairment of intangibles | - | 0 | - | - |
| Amortization of debt discount - related party | - | 0 | 0 | 0 |
| Interest accrued on note payable | - | - | 0 | 0 |
| Loss on extinguishment of note payable | - | 0 | 5,384,719 | - |
| Interest accrued on note payable related party | - | - | 0 | 0 |
| Net periodic pension benefit | - | - | 246,080 | 107,304 |
| Loss on extinguishment of series c preferred stock | - | 0 | 196,244 | - |
| Loss on impairment of inventory of entadfi | - | - | 0 | 0 |
| Net loss | -4,214,875 | 5,669,687 | -8,783,702 | -10,918,327 |
| Loss on issuance of preferred stock and warrants | - | 1,131,000 | 2,543,329 | - |
| Loss on impairment of goodwill | 8,134,000 | 12,000 | -12,000 | 11,512,000 |
| Depreciation and amortization | 5,398 | 3,336 | 3,387 | 8,447 |
| Stock-based compensation | 22,305 | 4,234 | 9,795 | 60,238 |
| Change in fair value of contingent warrant liability | 1,612 | 26,559 | -36 | -10,024 |
| Change in fair value of series e warrant liability | - | -4,486,847 | - | - |
| Change in fair value of series d derivative liability | -3,955,778 | - | - | - |
| Deferred tax benefit | - | 0 | 0 | 0 |
| Change in fair value of series e derivative liability | -2,072,590 | 1,539,014 | - | - |
| Amortization of deferred offering costs | - | 0 | - | - |
| Accounts receivable | -270,735 | 293,929 | -9,559 | -15,685 |
| Gain on settlement of contingent warrant liabilities | - | -944,694 | 0 | 944,694 |
| Inventories | -11,654 | -462 | 1,417 | 72,765 |
| Prepaid expenses, long-term | - | 0 | 0 | 0 |
| Investor receivable | -50,000 | 50,000 | - | - |
| Prepaid expenses and other current assets | 83,396 | 499,228 | -169,489 | -201,379 |
| Deferred offering costs | - | 75,000 | 150,000 | - |
| Accounts payable | -224,779 | -45,687 | -775,167 | -272,801 |
| Accrued expenses | -62,543 | -142,150 | -427,930 | -9,952 |
| Amortization of debt discounts | 0 | 3,922 | 115,196 | 4,966 |
| Change in fair value of subscription agreement liability related party | 0 | - | - | - |
| Payment of financing costs | - | 0 | 0 | 0 |
| Net periodic pension benefit | 0 | -619,399 | - | - |
| Proceeds from exercise of preferred investment options, net | - | 0 | 0 | - |
| Gain on forgiveness of accounts payable | 0 | 944,694 | - | - |
| Proceeds from exercise of stock options | - | 0 | 0 | 0 |
| Loss on impairment of inventory of entadfi | - | 0 | - | - |
| Disposal of property and equipment | 0 | -250 | -551 | -16,482 |
| Proceeds from issuance of notes payable - related party | - | 0 | 0 | 0 |
| Net cash used in operating activities | -2,121,481 | -3,090,585 | -3,177,829 | -3,409,976 |
| Proceeds from issuance of note payable | 247,196 | 460,875 | 400,000 | 475,000 |
| Proceeds from exercise of warrants | 384,842 | 0 | 0 | - |
| Cash in lieu of shares | 250 | 0 | 0 | 926 |
| Principal payments of notes payable | 0 | 164,188 | 5,410,029 | 1,537,331 |
| Payment for redemption of series c preferred stock | 0 | 0 | 0 | 1,713,570 |
| Proceeds from issuance of series d preferred stock and warrants | - | 0 | 9,301,200 | - |
| Proceeds from issuance of series e preferred stock and warrants | - | 6,250,000 | - | - |
| Proceeds from issuance of series c preferred stock and warrants | - | 0 | - | - |
| Proceeds from issuance of common stock in connection with the eloc | 0 | 21 | -21 | 6,391,655 |
| Net cash provided by financing activities | 631,788 | 6,546,708 | 4,291,150 | 3,614,828 |
| Effect of exchange rate changes on cash | -14,889 | 927,975 | -560,280 | -567,837 |
| Purchase of property and equipment | - | 0 | 0 | 0 |
| Net cash provided by (used in) investing activities | 0 | 0 | 0 | 0 |
| Net increase (decrease) in cash | -1,504,582 | 4,384,098 | 553,041 | -362,985 |
| Cash, beginning of period | 5,220,654 | 836,556 | 646,500 | - |
| Cash, end of period | 3,716,072 | 5,220,654 | 836,556 | - |
Onconetix, Inc. (ONCO)
Onconetix, Inc. (ONCO)